For this purpose, PBMCs from 4 patients with CLL and 6 healthy donors were incubated with increasing doses of lenalidomide (0.1 to 10 μM) for 7 days and the expression of ILT2 was evaluated on NK cells and B cells by flow cytometry. The gene discussed is LILRB1; the disease is B-cell chronic lymphocytic leukemia.